ГЕНЕТИЧЕСКИЕ АСПЕКТЫ ХИРУРГИЧЕСКОГО ЛЕЧЕНИЯ БОЛЬНЫХ С НАСЛЕДСТВЕННЫМ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ
https://doi.org/10.24884/0042-4625-2014-173-5-27-30
Аннотация
Numerous available results of investigations confirmed the important role of prophylactic bilateral laparoscopic salpingo-oophorectomy and contralateral prophylactic subcutaneous mastectomy in decrease of risks of malignant tumors of the reproductive system when mutation carriers of BRCA1 and BRCA2 presented. Recommendations to surgical treatment of hereditary breast cancer are considered as a very difficult task which should be based on risks and advantages of prophylactic surgical interventions. Presented surgical operations could be applied in mutation carriers of reparation DNA genes and patients with hereditary breast cancer aimed to improve the indices of general survival rate and quality of life.
Об авторе
Елена Михайловна Бит-Сава
Первый Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова; Санкт-Петербургский государственный педиатрический медицинский университет
Россия
Россия
Список литературы
1. Мерабишвили В. М. Онкологическая статистика (традиционные методы, новые информационные технологии): Руководство для врачей. Ч. I. СПб.: Коста, 2011. C. 220-221.
2. Adem C., Reynolds C., Soderberg C. L. et al. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers // Cancer. 2003. Vol. 1, № 1. Р. 1-11.
3. Domchek S. M., Friebel T. M., Neuhausen S. L. et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study // Lancet Oncol. 2006. № 7. Р. 223-229.
4. ESMO. Guidelines Working Group // Ann.Oncol. 2010. № 21 (Suppl. 5). Р. 20-22.
5. Frost M. H., Hoskin T. L., Hartmann L. C. et al. Contralateral prophylactic mastectomy: long-term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits // Ann. Surg. Oncol. 2011. Vol. 18, № 11. P. 3110-3116.
6. Geiger A. M., West C. N., Nekhlyudov L. et al. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy // J. Clin. Oncol. 2006. Vol. 24. P. 1350-1356.
7. Kauff N. D., Domchek S. M., Friebel T. M. et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA // J. Clin. Oncol. 2008. Vol. 26. P. 1331-1337.
8. Kauff N. D., Satagopan J. M., Robson M. E. et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation // N. Engl. J. Med. 2002. Vol. 346. P. 1609-1615.
9. Kelly A. M., Lubinski J., Ghadirian P. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: The hereditary breast cancer clinical study group. CO March 1. 2008. Vol. 26, № 7. P. 1093-109.
10. Meindl A., Ditsch. N, Kast K. et al. Hereditary Breast and Ovarian Cancer: New Genes, New Treatments, New Concepts // Dtsch. Arztebl. Int. 2011. Vol. 108, № 19. P. 323-330.
11. Metcalfe K. A. Prophylactic bilateral mastectomy for breast cancer prevention // J. Womens Health (Larchmt). 2004. Vol. 13, № 7. P. 822-829.
12. Rebbeck T. R., Friebel T., Lynch H. T. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers. The PROSE Study Group // J. Clin. Oncol. 2004. Vol. 22. P. 1055-1062.
13. Rebbeck T. R., Kauff N. D., Domchek S. M. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo - oophorectomy in BRCA1 or BRCA2 mutation carriers // J. Natl. Cancer Inst. 2009. Vol. 101. P. 80-87.
14. Rebbeck T.R., Lynch H. T., Neuhausen S. L. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations // N. Engl. J. Med. 2002. Vol. 346. P. 1616-1622.
15. Salhab M., Bismohun S., Mokbel K. Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery // BMC Womens Health. 2010. Vol. 28, № 10. P. 1186-1187.
16. Tercyak K., Peshkin B. N., Brogan B. M. et al. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing // J. Clin. Oncol. 2007. Vol. 5. P. 285-291.
17. Tilanus - Linthorst M. M., Alves C., Seynaeve C. et al. Contralateral recurrence and prognostic factors in familial non-BRCA1/2associated breast cancer // Br. J. Surg. 2006. Vol. 93. P. 961-968.
18. Willsher P., Ali A., Jackson L. Laparoscopic oophorectomy in the management of breast disease // ANZ. J. Surg. 2008. Vol. 78. P. 670-672.
Рецензия
Для цитирования:
Бит-Сава Е.М. ГЕНЕТИЧЕСКИЕ АСПЕКТЫ ХИРУРГИЧЕСКОГО ЛЕЧЕНИЯ БОЛЬНЫХ С НАСЛЕДСТВЕННЫМ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ. Вестник хирургии имени И.И. Грекова. 2014;173(5):27-30. https://doi.org/10.24884/0042-4625-2014-173-5-27-30
For citation:
Bit-Sava E.M. GENETICAL ASPECTS OF SURGICAL TREATMENT IN PATIENTS WITH HEREDITARY BREAST CANCER. Grekov's Bulletin of Surgery. 2014;173(5):27-30. (In Russ.) https://doi.org/10.24884/0042-4625-2014-173-5-27-30
Просмотров: 200
Послать статью по эл. почте 
